Study of ACR-2316 in Specific Advanced Solid Tumors
Specific Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4
6 insiders sold shares within a month
Since Aug 18, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 100 (planned)
- Started
- Oct 8, 2024
- Main results expected
- Aug 12, 2027
- Fully finished
- Dec 12, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation
Measured over: Number of DLT events during the DLT observation period (up to 28 days)
Dose Expansion
Measured over: RP2D supported by safety, PK and PD data through study completion
Dose Expansion
Measured over: Incidence and grades of TEAEs and TRAEs per NCI CTCAE v.5.0 and number of dose decreases, number of dose delays, and SAEs through study completion, an average of 1 year.
Dose Expansion
Measured over: Confirmed ORR per Recist v1.1 and DOR, CBR, assessed every 6 weeks from baseline thorough study completion, an average 1 year or until death.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4, since 2026-08-18, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06667141 · record last updated 2026-09-23 · checked 2026-11-09 15:47 UTC